BioDetection Systems b.v (BDS)

Twitter icon
Facebook icon
LinkedIn icon

Institution Description: 

BDS is an SME that develops, markets, and applies novel, effect-based detection methods for human biomonitoring and to determine chemical risks and monitor water quality and environmental- and food chain samples. Currently, more than 50 assays are used in panels to predict a wide range of toxicities. Quantitative, rapid effect-based screens include those for endocrine disruptors, as well as a range of emerging substances, genotoxic, and acutely toxic compounds. Reproductive (including developmental)-, non-genotoxic carcinogenicity, neurotoxicity, and immunotoxicity screens are being developed. Robotics is used to increase throughput of quantitative measurements and also for offline and online applications. Compound classes addressed with these effect-based screens include steroid hormones, thyroid hormones, retinoids, dioxins, PCBs, PAHs, EDCs, etc. BDS’ laboratories include a service department that is capable of carrying out analyses under ISO17025 and GMP+ certified conditions and a training facility for licensing its technology. It is a global player with world-wide commercial and R&D networks. BDS has extensive experience in FP program participation and coordination.

Involvement in DEMEAU: 

BDS will be leader of work area 4 on bioassay selection and comprehensive screening technologies for water quality. It will actively interact with and participate in the other technical WPs to apply these technologies in optimization and testing procedures of new treatment technologies and other demonstration projects. Furthermore, it will actively participate in activities to introduce and implement these technologies, including the removal of implementation barriers.